Posicor

mibefradil

A calcium-channel blocker that vasodilates without reflex tachycardia, which was used to manage hypertension or chronic stable angina. It was pulled from the market due to its inhibition of the liver metabolism of certain drugs (e.g., antihistamines) and statins, and increased mortality in patients with congestive heart failure.

Posicor®

Mibefradil, see there.
Mentioned in ?
References in periodicals archive ?
For instance, Posicor--a calcium channel blocker used to treat high blood pressure and chronic angina--was withdrawn after it was shown that certain drugs rose to dangerous levels when administered with Posicor.
This is another instance in a long line of postmarketing disasters including Rezulin, Cardura, and Posicor.
The eight drugs lately withdrawn were GlaxoSmithKline's Lotronex, for irritable bowel syndrome; American Home Products' Redux, a diet aid; the Bayer Corporation's Raxar, an antibiotic; Pfizer's Trovan, also an antibiotic; Roche's Posicor, a blood-pressure medication; Wyeth-Ayerst's Duract, a painkiller; Warner-Lambert's Rezulin, a diabetes drug; and, this spring, Organon's Raplon, an anesthetic.
Some drugs, such as Pondimin and Redux, had more adverse effects for women because they were prescribed mainly to women; others, such as Posicor, were prescribed equally to both women and men, and still had more adverse effects for women.
Wolfe: Raw milk, aspirin and Reye's Syndrome, tampons and toxic shock, Phenformin and lactic acidosis, Posicor and Duract are all instances where there was clear, unequivocal data at the FDA showing harm, but where the FDA failed to either ban a product or require necessary labeling.
Seldane, from Hoechst AG; and Posicor, marketed by Roche AG.
The withdrawals included the obesity drug Redux, the analgesic Duract, and the cardiac drug Posicor, which were withdrawn from the market for safety reasons within a year of approval.
Manufacturers Roche Products Ltd voluntarily decided to stop selling Posicor, which was launched last year and is marketed in 38 countries, including Britain.
for its alleged refusal to provide coverage for Viagra prescriptions; a class action suit filed in Federal court alleging that group health insurance plans have denied insurance coverage for Viagra users; a similar California suit against Aetna Life Insurance; a report on the 30 deaths possibly connected to the use of Viagra; a copy of a letter sent by Pfizer to doctors regarding the use of Viagra in combination with other drugs, including nitrates; and a warning by Roche Laboratories on the use of Viagra with its blood pressure drug Posicor.
Posicor - designed to treat angina and high blood pressure - was withdrawn from use eight days ago because of serious side-effects.
In the first 6 months of 1997, the following new drugs were approved by the FDA: Agrylin, Alesse, Anzemet, Carbatrol, Fareston, Flomax, Galzin, Idamycin, Migranal, Posicor, Prelay, Prevacid, Pytest, Requip, Resulin, Serlect, Skelid, Tasmar, Uniretic, Urso, Vicoprofen, Viracept, Zyban.
Since 1997, more than a dozen prescription drugs, including Pondimin, Redux, Seldane, Posicor, Duracht, Hismanal, Raxar, Rezulin, Propulsid, Lotronex, Raplon and Baycol, with serious side effects, have been taken off the shelves.